Arcturus Therapeutics (ARCT) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 20262027 catalysts and plans
Two mRNA programs have data catalysts in 2027: CF full phase II cohort 4 data in Q2; ARCT-2601 OTC deficiency top-line data in H2.
CF cohort 4 enrollment is continuing through year-end 2026; full data are targeted for Q2 2027, with top-line data expected in between and shared alongside the phase III decision.
If the CF program advances to phase III, Thermo Fisher is expected to contribute up to $40 million; preparation for the trial began in July 2026.
ARCT-2601 clinical trial startup is anticipated in early 2027; initial data from the reformulated candidate are expected in H2 2027.
LUNAR platform and pipeline
LUNAR is the lipid nanoparticle delivery technology; LUNAR 1.0 has established safety, tolerability and efficacy in an approved COVID vaccine across 30+ countries and in an OTC deficiency program.
LUNAR 2.0 showed 38 times better performance than LUNAR 1.0 in primates; the formulation is being applied to OTC deficiency with a focus on less frequent dosing and greater convenience.
The reformulated OTC candidate may enable monthly, lower-dose administration at home instead of clinic dosing every two weeks; this is a proposed goal, subject to clinical results.
PKU has been added to the pipeline, with an IND targeted for H2 2027; LUNAR 2.0 is presented as enabling liver targets that previously required impractical dosing frequency.
Cystic fibrosis program
The inhaled mRNA therapy aims to produce new CFTR protein in lung cells, addressing Class I patients who lack a transporter; about 15% of the CF population do not benefit from modulators, with roughly half of that group Class I.
Earlier dose-ranging tested 5, 10 and 15 mg once daily for about four weeks; CT scans at 10 mg showed improvements in mucus plugging and airway obstruction.
The ongoing 12-week study uses 10 mg once daily, enrolling up to 20 patients in the U.S., Turkey and Israel; measures include spirometry, lung clearance index, quality-of-life assessments and high-resolution CT.
Eligibility was narrowed to 45%–85% predicted lung function, and screening-to-baseline reproducibility criteria were tightened to reduce measurement variability.
Phase III go/no-go will consider the totality of lung-function, imaging and quality-of-life data; stability or improvement versus expected decline would be viewed positively.
Latest events from Arcturus Therapeutics
- LUNAR 2.0 advances mRNA programs alongside promising CF, OTC, and vaccine data.ARCT
Corporate presentation - Q3 net loss narrowed as LUNAR 2.0 advanced and 2027 clinical milestones approached.ARCT
Q3 2026 - ARCT-810 shows strong safety and efficacy; LUNAR 2.0 enables potent, convenient dosing and pipeline growth.ARCT
Status update - Upcoming phase II data and a pivotal CF decision mark major milestones for the mRNA pipeline.ARCT
H.C. Wainwright 28th Annual Global Investment Conference - Key clinical milestones for liver and lung mRNA therapies expected in the next 6–12 months.ARCT
12th Annual Cantor Fitzgerald Global Healthcare Conference - OTC phase II data and CF phase III decision expected soon, with major funding and tech advances.ARCT
Citigroup’s Biopharma Back to School Summit 2026 - Advancing mRNA therapies for CF and OTC with phase III plans, strong funding, and key partnerships.ARCT
Canaccord Genuity's 46th Annual Growth Conference - Advanced rare disease pipeline, regained vaccine rights, and secured Thermo Fisher partnership.ARCT
Q2 2026 - ARCT-810 delivers strong biomarker and safety results, with key data to be presented June 30, 2025.ARCT
Status Update